TREATMENT-FREE RESPONSE USING BRAZILIAN IMATINIB COPIES AS FIRST LINE -RESULTS FROM TWO PROSPECTIVE CLINICAL TRIALS
Several trials have demonstrated the feasibility of tyrosine kinase inhibitors (TKI) treatment in chronic myeloid leukemia (CML) patients with a deep molecular response, but little data is available about the results using imatinib copies. Brazil has been using imatinib copies as a first-line treatm...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | angličtina |
| Vydáno: |
2022
|
| On-line přístup: | https://doi.org/10.1016/j.htct.2022.09.362 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|